By targeting the TNF receptor–associated factor 3/enoyl-CoA hydratase 1 (TRAF3/ECH1) axis, they revealed an innovative approach to disrupt tumor metabolism while enhancing antitumor immunity (10). The gene discussed is ECH1; the disease is neoplasm.